EMA: Diabetes drugs with glargine do not raise cancer risk

06/3/2013 | Medscape (free registration)

Diabetes drugs containing insulin glargine do not appear to increase the risk of cancer in patients, the European Medicines Agency's Committee for Medicinal Products for Human Use concluded. The committee reviewed two new cohort studies as well as studies from a search of the scientific literature.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care